Stock Events

Heron Therapeutics 

$2.74
43
+$0.15+5.79% Tuesday 21:00

Statistics

Day High
2.76
Day Low
2.58
52W High
2.99
52W Low
0.5
Volume
1,960,217
Avg. Volume
2,072,401
Mkt Cap
411.2M
P/E Ratio
0
Dividend Yield
-
Dividend
-

Upcoming

Earnings

21MarExpected
Q2 2022
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Next
-0.55
-0.42
-0.28
-0.15
Expected EPS
-0.15
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HRTX. It's not an investment recommendation.

Analyst Ratings

4$Average Price Target
The highest estimate is $4.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Show more...
CEO
Barry Quart
Employees
203
Country
US
ISIN
US4277461020
WKN
000A1XB6K

Listings